BioSpace News Archive

Rejenevie™ Therapeutics announced the commencement of the company’s Phase II clinical trial to study the safety and effectiveness of its proprietary AR-100 immune restoration therapy to boost the function of the aging immune system

In the United States, half of all women and 20 percent of men age 50 and older will break a bone due to osteoporosis in their lifetime and many will die or be forced into nursing homes as a result.

Anji Pharmaceuticals, Inc. (“Anji” or “the Company”) today announced the acquisition of global development rights for a novel delayed-release formulation of metformin (Metformin DR). Originally developed by Elcelyx Therapeutics, Metformin DR is an investigational product designed to target metformin delivery to the lower small intestine.

Beam Therapeutics announced that John Evans, chief executive officer, will present a company overview at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 9:30 a.m. ET.

Gamida Cell Ltd. announced that its previously scheduled Annual Meeting of Stockholders will be webcast on Tuesday, June 4, 2019, at 10:00 a.m. ET at the offices of the company located at 5 Nahum Heftsadie Street, Givaat Shaul, Jerusalem 91340 Israel.

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Johanna Mercier will join the company as Chief Commercial Officer, and will become a member of the company’s senior leadership team.

The Mesothelioma Compensation Center says, “We are challenging a public utility, oil refinery or power plant worker in any state who has just been diagnosed with mesothelioma or their family to call us anytime at 800-714-0303 for on the spot access to attorney Erik Karst and his remarkable team at the law firm of Karst von Oiste.

Singlera Genomics, which focuses on non-invasive early cancer detection through circulating tumor DNA methylation haplotyping analysis, was selected as one of three finalists for the second annual AACC Disruptive Technology Award.

Puration, Inc. announced a new website published to accelerate the planed dividend of Nouveau, Inc. shares to PURA shareholders in conjunction with PURA’s spinoff of its cannabis cultivation operations to NOUV in the fourth quarter of last year.

Quest Diagnostics announced it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice precision medicine trial, the largest precision medicine trial of its kind.